a year ago

Amber Therapeutics Raises $100 Million for Urinary Incontinence Treatment

  • Amber Therapeutics, a London-based medical technology startup, has secured $100 million in Series A funding to advance its adaptive neuromodulation therapy for mixed urinary incontinence (MUI)

  • The company's flagship treatment, Amber-UI, is the first fully implantable adaptive neuromodulation therapy in clinical development for MUI

  • The funding round was led by New Enterprise Associates and included participation from F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC

  • The investment will support the company's pilot studies in Europe and the US, aiming to bring Amber-UI to US regulatory approval.

      • ProblemHealthcare

      "Millions of women suffer from mixed urinary incontinence, a debilitating condition that significantly impacts their quality of life, with current treatments often proving ineffective."

      Solution

      "Amber-UI is a first-of-its-kind, fully implantable adaptive neuromodulation therapy that targets the pudendal nerve through minimally invasive surgery, offering a potential breakthrough treatment for mixed urinary incontinence."

      Covered on